SNUG01 showed favorable safety and signs of early clinical efficacy in a recently completed investigator-initiated trial in China, the firm said.

With U.S. funding for science at risk, a longtime advocate sees ‘light at the end of the tunnel’ in Washington.

Q2 2025 Management View Chaim Lebovits, President and CEO, reaffirmed that "our top priority is advancing NurOwn into our ...

Athira Pharma (ATHA) presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers at the ALS Nexus 2025 conference in ...

Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to ...

It may be time to rethink certain genetic mutations associated with two devastating neurodegenerative disorders—amyotrophic ...

On Sunday, October 5, the San Diego community will come together for the 24th Annual Walk to Defeat ALS, a fundraising event ...

Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig’s disease, is an incurable neurological disorder affecting motor ...

After the success of last year’s benefit, The Young and the Restless’ Kate Linder is partnering with the ALS Network for another fundraiser to benefit ALS Research & Care on Sunday, August 17 ...

In partnership with ALS United Rocky Mountain, Nix sold "Bolieve" T-shirts and raised $10,000 for the nonprofit. "All of it goes to (ALS) research and finding ways to get on top of it. I think it ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive muscle weakness. A research team at Tohoku University and Keio University has uncovered a unifying ...